Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASCT 01
- Development stage
- Phase 2
- Lead developer
- Lifecells
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intra-arterial, Intramuscular
01
Overview
ASCT 01 is an autologous, bone marrow-derived stem cell therapy developed by Lifecells, LLC for the treatment of critical limb ischemia (CLI). The preparation consists of stem cells harvested from the patient's own bone marrow, which are then processed and administered via intra-arterial infusion and intramuscular injection into the affected limb. The therapeutic objective is to stimulate angiogenesis and improve blood perfusion in patients who have exhausted all conventional medical and surgical revascularization options. By promoting the formation of new collateral blood vessels, the therapy aims to alleviate ischemic pain, facilitate the healing of ulcers, and prevent major limb amputation.
- Other names
- autologous bone marrow-derived stem cell preparation
Beyond the preview
Go deeper on ASCT 01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASCT 01.